Inozyme Pharma Inc

Inozyme Pharma — Technical Presentation (January 2025)

25 slides from Inozyme Pharma's technical presentation, Jan 10, 2025

  1. Slide 1: Interim clinical and safety data of INZ-701 in infants and young children with ENPP1 Deficiency

    Exhibit 99.2 Interim clinical and safety data of INZ-701 treatment in infants and young children with ENPP1 Deficiency and key program updates January 2025 Ella Living with ENPP1 Deficiency

  2. Slide 2: Legal disclaimer

    Legal disclaimer This presentation and any statements made orally during this presentation contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you

  3. Slide 3: Strong progress advancing INZ-701 across multiple indications and demographics

    Strong progress advancing INZ-701 across multiple indications and demographics Milestones to Date January 2025 Updates üPositive clinical effects observed in adults • Clinical improvements in multiple measures with ENPP1 Deficiency and ABCC6 Deficiency of disease from baseline observed in infants in

  4. Slide 4: GACI: A severe manifestation of ENPP1 Deficiency in infants

    Generalized arterial calcification of infancy (GACI): A severe manifestation of ENPP1 Deficiency in infants Significant morbidity and mortality in infants and children with GACI Vascular Calcification 50% Mortality within the first 6 months due to severe cardiovascular complications ~10% 95% of norm

  5. Slide 5: INZ-701 treatment in infants and very young children with GACI

    INZ-701 treatment in infants and very young children with GACI Two ongoing programs evaluating safety and clinical effects ENERGY 1 Expanded Access Program 3 infants treated 2 infants + 1 toddler treated Phase 1b, global, open-label study in patients <1 yr old Open-label treatment for ENPP1 Deficien

  6. Slide 6: Clinical improvements in multiple measures of disease from baseline

    Clinical improvements in multiple measures of disease from baseline observed with INZ-701 treatment Natural history INZ-701 treatment 80% 50% of treated infants thriving beyond 1 year of age Mortality within the first 6 months due to severe cardiovascular complications Improved survival observed Sub

  7. Slide 7: Significant disease burden at baseline in GACI infants and children

    Significant disease burden at baseline in GACI infants and children Impaired heart function, substantial ectopic calcifications, hypophosphatemia and systemic hypertension are common; Some patients entering age for rickets development Study Arterial Systemic Joint/soft tissue Age for Status LVEF Hyp

  8. Slide 8: INZ-701 treatment observations in GACI infants and children

    INZ-701 treatment observations in GACI infants and children Evidence of improved heart function, stabilization or reduction in ectopic calcifications and hypophosphatemia, and prevention of rachitic changes Study Arterial Systemic Joint/soft tissue Age for Status LVEF Hypophosphatemia Rickets Patien

  9. Slide 9: Improved survival observed

    Study Status Improved survival Patient ID/ Age at Age at Tx [Time on diagnosis Start in GACI observed: Alive/Dead Tx] E1 Pt1 2.6 mo 8.5 mo A [16 mo] 80% of treated infants E1 Pt2 thriving with 11+ 4.4 mo 10.5 mo A [15 mo] months of treatment E1 Pt3 26 d 1 mo D [3 wks] EAP-01 1.5 mo 2 yrs 5 mo A [22

  10. Slide 10: Reduced or stabilized arterial calcifications observed

    Study Arterial calcifications Reduced or Patient ID/ Age at Age at Tx [Time on diagnosis Start stabilized arterial Baseline Treatment Tx] calcifications E1 Pt1 2.6 mo 8.5 mo Yes (M) Stable [16 mo] observed: E1 Pt2 4.4 mo 10.5 mo NR Stable [15 mo] Key driver of morbidity E1 Pt3 26 d 1 mo Yes (M) NA [

  11. Slide 11: Case EAP-03: Complete resolution of arterial calcification observed

    Case EAP-03: Evidence of complete resolution of arterial calcification observed Baseline Baseline 6-month follow-up 6-month follow-up Abdominal Abdominal aorta and aorta renal arteries Aorta and Carotid pulmonary arteries artery efflux NG Tube 11 EAP data cut: 13 Dec 2024 Calcification

  12. Slide 12: Evidence of improved heart function observed

    LVEF Evidence of Study Patient ID/ Age at diagnosis Age at Tx Start improved heart [Time on Tx] Baseline Treatment function observed: E1 Pt1 2.6 mo 8.5 mo 62% Stable [16 mo] Stabilization or improvement in E1 Pt2 4.4 mo 10.5 mo 64% Stable [15 mo] left ventricular ejection fraction (LVEF) in all surv

  13. Slide 13: Ejection fraction was stable or improved with INZ-701 treatment

    Ejection fraction was stable or improved with INZ-701 treatment E1 Pt1 E1 Pt2 100 100 Normal infant EF % (Tissot et al, Age = 1yr 8.5 mo Age = 1yr 10.5 mo 80 80 Front Pediatr. 2018 Apr 4;6:79) 60 60 40 40 20 20 0 0 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Time on treatment (Weeks) Time on treatment (

  14. Slide 14: Reduced risk of rickets observed

    Age for Reduced risk Hypophosphatemia Rickets Study rickets risk Patient ID/ Age at Age at Tx [Time on diagnosis Start of rickets Tx] Baseline Treatment Current Status observed: E1 Pt1 ↑ to/near 2.6 mo 8.5 mo Yes Yes No normal [16 mo] Increased or stabilized E1 Pt2 Stable phosphate levels in all 4.4

  15. Slide 15: Serum phosphate was stable with INZ-701 treatment in patients at risk for ARHR2

    Serum phosphate was stable with INZ-701 treatment in all patients at risk for ARHR2 Natural History: Patients with ENPP1 Deficiency who survive the critical period of infancy develop hypophosphatemia E1 Pt1 E1 Pt2 7 7 5.6 6 5.0 6 4.3 5 5 3.7 4 3.1 4 2.5 3 3 1.9 Age = 1 yr 8.5 mo 1.2 2 Study patients

  16. Slide 16: Serum phosphate was stable or improved in patients at risk for rickets

    Serum phosphate was stable or improved with INZ-701 treatment in patients at risk for rickets • Serum phosphate levels (LLN) decreased slightly over time in healthy individuals (black line) 6 LLN* • By 1 year of age, ENPP1 deficient patients are ENPP1 Def^ already hypophosphatemic 4 E1 Pt1 E2 Pt2 •

  17. Slide 17: INZ-701 exhibited a favorable safety profile in ENERGY and EAP patients

    INZ-701 exhibited a favorable safety profile in ENERGY 1 and EAP patients No. of Patients No. of Patients Total adverse AEs related to AEs not related to Serious AEs (SAEs) SAEs not related to with AEs events (AEs) INZ-701 INZ-701 related to INZ-701 INZ-701 reported 2 4 ENERGY 1 (n=3) 34 0 2 0 1 Exp

  18. Slide 18: ADA response observed in youngest patients

    ADA response observed in youngest patients ADAs absent in toddler and transient in one infant Anti-Drug Antibody (ADA) Status/Titers Weeks 5 13 19 20 21 24 26 27 29 30 34 37 38 39 43 52 79 Subject ID E1 Pt1 320 80 40 80 E1 Pt2 2,560 10,240 10,240 10,240 40,960 20,480 81,920 EAP-01 EAP-02 1,280 40,96

  19. Slide 19: ADAs blunt but do not eliminate post-dose PPi increases

    ADAs blunt but do not eliminate potentially beneficial post-dose E1 Pt2 PPi increases 2,560 600 Fold 5,120 Subject ID PPi (nM) Day 400 change 91 pre-dose 325 -- 200 10,240 91+4 hrs post-dose 545 1.7X E1 Pt2 0 80 100 120 140 160 119 pre-dose 71 -- Days 119 +24 hrs post-dose 329 4.6X EAP-02 40,960 100

  20. Slide 20: Case EAP-03: Resolution of arterial calcification despite ADA detection

    Case EAP-03: Evidence of complete resolution of arterial calcification observed despite ADA detection JAN’24 FEB’24 MAR’24 APR’24 MAY’24 JUN’24 JUL’24 st 1 INZ-701 dose Baseline CT ADAs detected INZ-701 dose increase Follow up CT (1.8 mg/kg) (2.4 mg/kg) Baseline Baseline 6-month follow-up 6-month fo

  21. Slide 21: Five patients continue receiving long-term, home administration of INZ-701

    Five patients continue receiving long-term, home administration of INZ-701 No safety signals Data Review Committee recommended continuing Transient exposure and PPi response expected following each dose treatment of all patients following review of interim Potential for tolerization with long-term l

  22. Slide 22: Positive interim data supports growing body of evidence for INZ-701 in all age groups

    Positive interim data in infants and very young children supports growing body of evidence for INZ-701 use in all age groups Positive interim safety Infant data intended to support approval and exploratory efficacy data package for broad commercial label Well-tolerated when administered to infants a

  23. Slide 23: ASPIRE: Planned Pivotal Study in Pediatric Patients with ABCC6 Deficiency

    ASPIRE: Planned Pivotal Study in Pediatric Patients with ABCC6 Deficiency

  24. Slide 24: ASPIRE: Planned pivotal study in pediatric patients with ABCC6 Deficiency

    ASPIRE: Planned pivotal study in pediatric patients with ABCC6 Deficiency Preliminary support from U.S. and EU regulators for ASPIRE pivotal trial in children with ABCC6 Deficiency Population: Infants and Design: Multicenter, multinational, randomized (1:1), open label, conventional therapy control

  25. Slide 25: Thank you

    Thank you

Inozyme Pharma — Technical Presentation (January 2025) on 6ix